NewAmsterdam Pharma (NAMS) Earnings Analysis
NewAmsterdam Pharma (NAMS) has no confirmed upcoming earnings date. Last quarter (2026-05-07) it beat with EPS -0.4 USD vs -0.46 USD est (+13%). It has beaten estimates in 1/4 recent quarters (25%). Trailing P/E -17.51.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does NAMS next report earnings?
No confirmed upcoming earnings date is currently scheduled for NAMS. This page updates as the calendar is published.
NAMS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-07 | -0.4 USD | -0.46 USD | +13% | Beat |
| 2026-02-18 | -0.63 USD | -0.4342 USD | -45.1% | Miss |
| 2025-05-08 | -0.49 USD | -0.45 USD | -8.9% | Miss |
| 2025-02-26 | -0.95 USD | -0.48 USD | -97.9% | Miss |
Beat rate: 1/4 (25%) over reported quarters with consensus data.
NAMS valuation and analyst view
| Trailing P/E | -17.51 |
|---|---|
| Trailing EPS | -1.75664 USD |
| Price / book | 5.77 |
| Dividend yield | 0.00% |
| Market cap | 3.70B |
| Analyst consensus | Buy (9 buy / 1 hold / 0 sell) |
| Avg price target | 51.33 USD |
Related research pages
Frequently asked questions
When is NewAmsterdam Pharma (NAMS)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for NAMS. This page updates as the calendar is published.
Did NAMS beat earnings last quarter?
In its 2026-05-07 report, NAMS posted EPS of -0.4 USD versus a -0.46 USD estimate — a beat of 13%.
What is NAMS's earnings track record?
Over the last 4 reported quarters with consensus data, NAMS beat estimates 1 times (25%).
What is NAMS's current P/E ratio and EPS?
NAMS trades at a trailing P/E of -17.51 on trailing EPS of -1.7566359075989348 USD.
What do analysts rate NAMS?
Analyst consensus is "Buy" across 10 ratings (0 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell). Average 12-month price target: 51.33 USD.